key: cord-0800999-lv91wqk1
authors: Xu, Zhaowei; Li, Yang; Lei, Qing; Huang, Likun; Lai, Dan-yun; Guo, Shu-juan; Jiang, He-wei; Hou, Hongyan; Zheng, Yun-xiao; Wang, Xue-ning; Wu, Jiaoxiang; Ma, Ming-liang; Zhang, Bo; Chen, Hong; Yu, Caizheng; Xue, Jun-biao; Zhang, Hai-nan; Qi, Huan; Yu, Siqi; Lin, Mingxi; Zhang, Yandi; Lin, Xiaosong; Yao, Zongjie; Sheng, Huiming; Sun, Ziyong; Wang, Feng; Fan, Xionglin; Tao, Sheng-Ce
title: COVID-ONE-hi: The One-stop Database for COVID-19 Specific Humoral Immunity and Clinical Parameters
date: 2021-11-05
journal: Genomics Proteomics Bioinformatics
DOI: 10.1016/j.gpb.2021.09.006
sha: 80206c709a1641c27d7c93a4cf5a96345b222f23
doc_id: 800999
cord_uid: lv91wqk1

Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19 specific IgG/IgM immune responses and clinical parameters (COVID-ONE-hi). COVID-ONE-hi is based on the data that contain the IgG/IgM responses to 21 of 28 known SARS-CoV-2 proteins and 197 spike protein peptides against 2,360 serum samples collected from 783 COVID-19 patients. In addition, 96 clinical parameters for the 2,360 serum samples and information for the 783 patients are integrated into the database. Furthermore, COVID-ONE-hi provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-hi is freely available at www.COVID-ONE.cn.

COVID-19 is an unprecedented global threat caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has already caused 209,308,033 infections and claimed 4,393,014 lives as of August 19, 2021 (https://coronavirus.jhu.edu/map.html) [1] . There is still no effective medicine [2, 3] for COVID-19.

Most patients recover via their own immunity, including SARS-CoV-2 specific IgG responses, especially neutralizing antibodies [4] [5] [6] . Overall, it is of great interest to decipher SARS-CoV-2 specific IgG and IgM responses at a systems level and to correlate antibody responses to clinical parameters.

To understand how the human immune system responds to SARS-CoV-2, we constructed a SARS-CoV-2 proteome microarray containing 18 of the 28 predicted proteins and applied it to characterize IgG and IgM antibodies for the sera of 29 convalescent patients [7] . Recently, we upgraded the SARS-CoV-2 protein microarray, and the new microarray contains 21 predicted SARS-CoV-2 proteins and 197 spike protein peptides (with full coverage of spike) [8] . Using this microarray, we screened 2,360 serum samples from 783 COVID-19 patients, covering mild, severe and critical cases. Thus, we compiled a dataset with comprehensive information on SARS-CoV-2 specific antibody responses and rich in clinical parameters.

To share the dataset efficiently, in addition to the related research that we have already published [9] [10] [11] [12] [13] , we built a database for COVID-19 specific humoral immune responses and clinical parameters, namely, COVID-ONE-hi (www.covid-one.cn), using Shiny. This database contains a comprehensive dataset of IgG and IgM response to the 21 predicted SARS-CoV-2 proteins and 197 spike protein peptides from a cohort of 783 COVID-19 patients. To bolster clinical relevance, 96 clinical parameters and basic patient information were also included. COVID-ONE-hi provides search, data analysis, and visualization functions. In particular, COVID-ONE-hi integrates antibody response landscape analysis, correlation analysis, machine learning, etc. In the data analysis module, users can easily define sample group of interest by adjusting scale bars, and the sample group can be either one group or paired groups. In-depth analysis is achieved by clicking a single button; optionally, the results can be saved and downloaded as an independent package for further analysis. 4 To our knowledge, COVID-ONE-hi is the first database for SARS-CoV-2 specific humoral immune responses. We believe that COVID-19 humoral immunity will be of broad interest and will facilitate understanding of immune responses in COVID-19 to combat the pandemic.

COVID-ONE-hi is a Shiny-based (1.5.0) database. Shiny dashboard (0.7.1) and Shiny BS (0.61) were used to shape the UI, and the package DT (0.15) was used to format data tables. For data analysis, dplyr (1.0.2), tidyverse (1.3.0), randomForest (4.6-14), pROC (1.16.2), and umap (0.2.6.0) were integrated into Shiny. Pheatmap (1.0.12) and ggplot2 (3.3.2) carry out plotting. For the basic environment, the operation system is Ubuntu 20.04 LTS, and the version of R is 3.6.3.

To calculate the rate of antibody response for each protein, the mean plus 2 times standard deviation (SD) of the control serum was set as the cut-off. R was used for most data analysis and drawing, i.e., Pearson correlation coefficient, ROC, T-test, cluster analysis and machine learning.

The database framework and clinical information for the patients In this study, we collected 2,360 serum samples from 783 patients with an average age of 61.4 years and average onset time of 50 days. There were 387 males, 396 females and 369 non-severe, 309 severe, 105 critical cases. Regarding outcome, there were 723 survivors and 60 non-survivors ( Figure 1A , Table 1 and Table S1 ).

To systematically analyze immune responses to SARS-CoV-2 infection, we screened 2,360 serum samples using SARS-CoV-2 protein microarray that contains 21 proteins and 197 spike protein peptides. Additionally, we analyzed 89 blood parameters for the 2,360 serum samples, i.e., complete blood count, blood chemistry study and blood enzyme tests. Hence, we obtained a comprehensive dataset that contains SARS-CoV-2 specific humoral responses and clinical parameters.

By combining clinical information, IgG/IgM immune responses and blood parameters, we established a database (COVID-ONE-hi) that provides a one-stop analysis pipeline for COVID-19 specific immune responses and clinical parameters ( Figure 1B ). To help users obtain more COVID-19 serum profiling data, we set up a 5 page on the COVID-ONE-hi website, named "More studies", to archive other highly related data of COVID-19 serum profiling (protein/peptide microarray/phage display) [14] [15] [16] [17] [18] [19] . In addition, a healthy control dataset was added to the HELP page, which contains the IgG and IgM responses for 528 healthy people against the 21 proteins and spike protein peptides (Table S2 ).

The following three steps are included in the analysis module: Users select a set of samples in the panel of patient information and click START. COVID-ONE-hi filters candidate samples according to the given parameters. COVID-ONE-hi conducts analysis and provides results on the webpage.

To demonstrate how to use COVID-ONE-hi for analysis, we provide 2 cases for single group and paired groups as examples.

To study the features of dead COVID-19 patients, we selected the "death" parameter of outcome in a single-group analysis module. This cohort contained 392 serum samples from 60 patients, with an average age of 69.6 years and gender (38 male, 22 female) ( Table 2 ). The IgG response landscape analysis of SARS-CoV-2 proteins show positive rates of S1 protein, N protein and ORF3b are 95%, 93% and 87%, respectively, which consistent with previous studies [20, 21] (Figure 2A) .

Interestingly, NSP7 has 88% IgG positive rate, suggesting that NSP7 may play an important role in COVID-19 ( Figure 2A ). Spike peptide S1-45 has the highest positive rate (87%) for the IgM response, indicating that the region including S1-45 may play an important role in IgM immunity ( Figure S1 ).

Correlation analysis of clinical parameters show that the neutrophil count has negative correlation with the monocyte count and lymphocyte ratio ( Figure 2B ). In addition, correlation analysis of antibody IgG responses show high correlation for IgG responses of the S1 and N proteins, but not for S2 protein, with all non-structural protein IgG responses having no or very weak correlations ( Figure 2C ). To study influencing factors of S1 antibody production, we analyzed correlation between the S1 IgG responses and clinical parameters, and found S1 antibody responses correlate with globulin ( Figure 2D ). 6 Previous studies showed that gender has considerable effect on the severity and outcome of COVID-19 [22, 23] and is associated with underlying differences in immune responses to infection [24] . To study differences in IgG/IgM immune responses and clinical parameters between the genders, we defined Group 1 as female and Group 2 as male for severe patients, with 231 males at average age of 64.3 and 183 females at average age of 68.1. Consistent with previous studies [25] , males had a higher risk of severe COVID-19 than females (231/377 vs 183/379, p < 0.001) (Tables 3 and 4) .

UMAP results show no overall difference in IgG immunity between males and females ( Figure 3A) . To explore the disease mechanism in the genders, we performed in-depth analysis for antibody responses and blood parameters using COVID-ONE-hi.

The antibody response landscape shows that male patients have higher positive rates than females for ORF-9b IgG, RdRp IgG, NSP1 IgG, etc. ( Figure 3B ). Moreover, longitudinal antibody dynamic analysis shows a stronger ORF-9b IgG response in males during the whole period of symptom onset, with a stronger NSP1 IgG response during the early stage of symptom onset, and no significant difference for RdRp IgG ( Figure 3C -E). ORF-9b has been considered a drug target for the treatment of COVID-19 because it suppresses type I interferon responses [26] [27] [28] . To explore the relevance between ORF-9b antibody responses and COVID-19 severity, we compared ORF-9b antibody responses between mild and severe cases in different gender, and the results show that males with severe COVID-19 have higher ORF-9b antibody responses than females ( Figure 3F -G).

To further decipher differences between female and male patients of COVID-19, we employed random forest for machine learning. The results show creatinine, which is an acute kidney injury marker, to be the most significant factor between males and females ( Figure 4A) . To explore the relevance between creatinine and gender in COVID-19, we compared the level and dynamic response of creatinine in males and females and observed that the creatinine level in males are significantly higher than that in females ( Figure 4B and C) . To explore the relevance between creatinine and COVID-19 severity, we compared creatinine levels in mild and severe cases. Similar to ORF-9b antibody responses, male patients with severe COVID-19 have a higher level of creatinine ( Figure 4D and E) . Hence, ORF-9b antibodies and creatinine are associated with severe disease in male patients, which suggests different pathogeneses and complications between male and female COVID-19 patients. 7 

In this study, we built COVID-ONE-hi, a COVID-19 specific database, using R Shiny. COVID-ONE-hi is based on a comprehensive dataset generated by analyzing 2,360 COVID-19 sera using the SARS-CoV-2 protein microarray containing 21 of the 28 known SARS-CoV-2 proteins and 197 peptides completely covering the entire spike protein sequence.

There are several published studies identifying the clinical characteristics, biomarkers and specific antibody responses of diverse COVID-19 patients (Table S3) .

To strengthen the credibility of our dataset, we compared SARS-CoV-2 specific antibody responses with other studies at different levels. At the protein level, we analyzed the dynamic response to the S1 and N proteins. The results show that S1 and N responses peaked at 6 weeks after the onset of symptoms for IgG and 4 weeks for IgM, which is consistent with the results of previous studies [18, 20] (Figure S2) . At the peptide level, we compared IgG recognition of immunodominant regions in the SARS-CoV-2 spike protein and found that some high response areas that we identified [12] are consistent with those of Shrock et al. [14] : infection when combining N and spike protein [19] . In our study, the AUC of the N protein is 0.995 for IgG and 0.988 for IgM, and the AUC of the S1 protein is 0.992 for IgG and 0.992 for IgM. We also found that S2-78 (aa 1148-1159) IgG is comparable to S1 IgG for COVID-19 patients, with an AUC of 0.99 for IgG and 0.953 for IgM [11] . (Table S4) , and thus will be of broad interest for researchers and clinicians from diverse backgrounds. (ii) Accessibility: COVID-ONEhi provides a one-stop analysis pipeline, by which users can easily obtain meaningful information. (iii) Scalability: COVID-ONE-hi is built on the R platform, which is freely accessible, and many modular tools are readily available; thus, we can easily 8 expand and incorporate new analysis for the dataset whenever necessary without changing the overall structure of the database. Nonetheless, there are some limitations for COVID-ONE-hi. For example, it lacks data for convalescent patients, peptidelevel humoral responses to proteins other than S protein, and multicentre samples. In the future, we will analyze the dynamic responses of SARS-CoV-2 specific antibodies using ~500 serum samples from ~100 COVID-19 convalescent patients. We will also integrate published peptide microarray/phage display-related data [14] [15] [16] 29 ] and attempt to update the database covering the whole SARS-CoV-2 proteome at the peptide or amino acid level. In addition, the SARS-CoV-2 protein microarray has already been promoted by CDI Labs (www.cdi.bio) and ArrayJet (www.arrayjet.co.uk), and we anticipate more diverse data for SARS-CoV-2 specific antibody responses from multicentre samples. We strongly believe that by sharing a large dataset and facilitating data analysis, COVID-ONE-hi will be a valuable resource for COVID-19 research. Table 1 The clinical information of involved patients Table 2 Serum sample information of Case Ⅰ Table 3 Serum sample information of Case Ⅱ Table 4 The binary logistic regression parameter of severity in association with the gender among COVID-19 patients

File S1 The methods of protein microarray construction and serum profiling Figure S1 The antibody IgM response landscape against SARS-CoV-2 proteins (upper part), S1 protein peptides (middle part) and S2 protein peptides (lower part)

Scatter plot shows dynamic antibody responses to S1 protein IgG (A), N protein IgG (B), S1 protein IgM (C), and N protein IgM (D). Table S3 Other relevant studies of COVID-19 serum profiling   Table S4 The 

An interactive web-based dashboard to track COVID-19 in real time

Ensuring vaccine safety

Understanding COVID-19 vaccine efficacy

Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Not just antibodies: B cells and T cells mediate immunity to COVID-19

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients

SARS-CoV-2 antibody signatures for predicting the outcome of COVID-19

Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections

Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients

Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients

Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins

Viral epitope profiling of COVID -19 patients reveals cross-reactivity and correlates of severity

SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution

SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients

Peptide microarraybased analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development

SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19

Analysis of SARS-Co V-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray

Antibody responses to SARS-Co V-2 in patients with COVID-19

ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection

Factors associated with COVID-19-related death using OpenSAFELY

Considering how biological sex impacts immune responses and COVID-19 outcomes

Sex differences in immun e responses that underlie COVID-19 disease outcomes

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70

The authors declare no competing interests.